Topic Hub
59 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 59 of 59 clinical reviews.
A detailed head-to-head comparison of dapagliflozin (Farxiga) and insulin glargine (Lantus) across special populations including heart failure, CKD, elderly patients, and type 1 diabetes, with trial data and prescribing guidance.
Read clinical reviewA clinical deep-dive into dapagliflozin (Farxiga) versus insulin glargine (Lantus), why physicians combine them in type 2 diabetes, and the specific risks to monitor when doing so.
Read clinical reviewA clinical comparison of dapagliflozin (Farxiga) vs insulin glargine (Lantus) for long-term glycemic durability, cardiovascular outcomes, weight, and hypoglycemia risk in type 2 diabetes.
Read clinical reviewA deep comparison of Farxiga (dapagliflozin) vs Lantus (insulin glargine) using real-world evidence, head-to-head data, cardiovascular outcomes, and clinical decision guidance from HealthRX physicians.
Read clinical reviewA clinical comparison of dapagliflozin (Farxiga) and insulin glargine (Lantus) covering titration speed, tolerability, hypoglycemia risk, weight effects, and when to switch, reviewed by the HealthRX medical team.
Read clinical reviewA clinical guide comparing dapagliflozin (Farxiga) and insulin glargine (Lantus) for type 2 diabetes, covering when each agent fails, how to switch safely, and what the evidence says about sequencing these therapies.
Read clinical reviewA detailed head-to-head comparison of dapagliflozin (Farxiga) versus metformin across special populations including heart failure, CKD, older adults, and pregnancy. Evidence-based guidance from named trials and current guidelines.
Read clinical reviewA clinical comparison of dapagliflozin (Farxiga) and metformin for type 2 diabetes, including the evidence base for combining both agents, switching considerations, and safety data from major trials.
Read clinical reviewA head-to-head clinical comparison of dapagliflozin (Farxiga) and metformin for long-term glycemic durability, cardiovascular outcomes, weight, and real-world persistence in type 2 diabetes.
Read clinical reviewA detailed, evidence-based comparison of dapagliflozin (Farxiga) and metformin for blood sugar control, weight, cardiovascular outcomes, and safety, using clinical trial and real-world data.
Read clinical reviewA clinical comparison of dapagliflozin (Farxiga) vs metformin covering titration schedules, tolerability profiles, glycemic efficacy, and guidance on switching between the two agents.
Read clinical reviewA clinical comparison of dapagliflozin (Farxiga) and metformin for type 2 diabetes, including what your next step should be when one drug stops working or is not tolerated.
Read clinical reviewA detailed clinical comparison of dapagliflozin (Farxiga) and insulin degludec (Tresiba) across special populations including heart failure, CKD, elderly patients, and type 1 diabetes. Evidence-based guidance from HealthRX's medical team.
Read clinical reviewA clinical deep-dive into dapagliflozin (Farxiga) versus insulin degludec (Tresiba), covering why combining them makes sense, who benefits, what the safety data show, and when to switch or add one to the other.
Read clinical reviewA head-to-head clinical comparison of dapagliflozin (Farxiga) and insulin degludec (Tresiba) for long-term blood sugar control, cardiovascular outcomes, and durability of glycemic response, reviewed by the HealthRX medical team.
Read clinical reviewA clinical comparison of dapagliflozin (Farxiga) and insulin degludec (Tresiba) using real-world evidence, landmark trials, and guideline recommendations to help patients and clinicians make informed treatment decisions.
Read clinical reviewA clinical comparison of dapagliflozin (Farxiga) and insulin degludec (Tresiba) covering titration protocols, tolerability profiles, hypoglycemia risk, weight effects, and when to switch or combine therapies.
Read clinical reviewDapagliflozin (Farxiga) and insulin degludec (Tresiba) work through completely different mechanisms. Learn when each drug fails, why it fails, and the evidence-based steps your clinician should take next.
Read clinical reviewEmpagliflozin (Jardiance) vs dapagliflozin (Farxiga) across heart failure, CKD, elderly patients, and type 2 diabetes: trial data, real-world evidence, and clinical decision guidance.
Read clinical reviewA clinician-reviewed comparison of empagliflozin (Jardiance) and dapagliflozin (Farxiga), covering whether combining both SGLT2 inhibitors is rational, what the evidence shows, and when switching makes more sense than stacking.
Read clinical reviewA head-to-head clinical comparison of empagliflozin (Jardiance) and dapagliflozin (Farxiga) for long-term glycemic durability, cardiovascular outcomes, and kidney protection, with trial data and prescribing guidance.
Read clinical reviewA physician-reviewed comparison of empagliflozin (Jardiance) vs dapagliflozin (Farxiga) drawing on EMPA-REG OUTCOME, DAPA-HF, DECLARE-TIMI 58, and real-world registry data to guide clinical decision-making.
Read clinical reviewA clinical comparison of empagliflozin (Jardiance) vs dapagliflozin (Farxiga) covering titration schedules, tolerability profiles, glycemic efficacy, cardiovascular and renal outcomes, and guidance on switching between the two SGLT2 inhibitors.
Read clinical reviewEmpagliflozin (Jardiance) and dapagliflozin (Farxiga) are both SGLT2 inhibitors, but their cardiovascular and renal outcome trial data differ. This guide explains when switching makes clinical sense, when it does not, and what comes next.
Read clinical reviewEmpagliflozin (Jardiance) vs insulin glargine (Lantus) across special populations including CKD, heart failure, elderly patients, and obesity. Evidence-based clinical comparison with trial data, dosing guidance, and switching protocols.
Read clinical reviewA clinical deep-dive into empagliflozin (Jardiance) versus insulin glargine (Lantus): when each is used, why combining them makes pharmacological sense, and what risks to monitor when both are prescribed together.
Read clinical reviewA clinical comparison of empagliflozin (Jardiance) and insulin glargine (Lantus) for long-term glycemic durability in type 2 diabetes, covering trial evidence, HbA1c trajectories, cardiovascular outcomes, and when switching makes sense.
Read clinical reviewA head-to-head comparison of empagliflozin (Jardiance) and insulin glargine (Lantus) using real-world evidence, landmark trials, and current clinical guidelines to help clinicians and patients make informed treatment decisions.
Read clinical reviewA head-to-head clinical comparison of empagliflozin (Jardiance) and insulin glargine (Lantus) covering titration speed, tolerability, cardiovascular outcomes, hypoglycemia risk, and when to switch. Reviewed by the HealthRX medical team.
Read clinical reviewEmpagliflozin (Jardiance) and insulin glargine (Lantus) work by completely different mechanisms. When one stops controlling blood sugar, the next step depends on why it failed, not just which drug you were taking. This guide covers the clinical evidence, switching criteria, and combination strategies.
Read clinical reviewA clinical comparison of empagliflozin (Jardiance) and metformin across special populations including CKD, heart failure, elderly patients, and obesity. Evidence-based guidance on choosing, combining, or switching between these two type 2 diabetes agents.
Read clinical reviewA clinical comparison of empagliflozin (Jardiance) and metformin for type 2 diabetes: when to combine them, when to switch, cardiovascular and renal benefits, safety signals, and dosing guidance backed by named trials and FDA labeling.
Read clinical reviewA deep clinical comparison of empagliflozin (Jardiance) vs metformin for long-term glycemic durability, drawing on EMPA-REG OUTCOME, UKPDS 34, and real-world cohort data to guide treatment decisions.
Read clinical reviewA thorough, clinician-reviewed comparison of empagliflozin (Jardiance) and metformin using real-world data, landmark trials, and current guidelines to help patients and providers make informed treatment decisions.
Read clinical reviewA clinical comparison of empagliflozin (Jardiance) and metformin titration speed, tolerability, and glycemic outcomes, with trial data, dosing schedules, and guidance on switching.
Read clinical reviewA clinical comparison of empagliflozin (Jardiance) and metformin for type 2 diabetes, with evidence-based guidance on what to do when either drug stops working or causes intolerable side effects.
Read clinical reviewA direct clinical comparison of empagliflozin (Jardiance) and insulin degludec (Tresiba) across special populations including elderly patients, those with CKD, heart failure, and type 1 diabetes. Reviewed by the HealthRX medical team.
Read clinical reviewA head-to-head analysis of empagliflozin (Jardiance) and insulin degludec (Tresiba) using real-world evidence, landmark trials, and clinical guidelines to help patients and clinicians make informed treatment decisions.
Read clinical reviewA clinical comparison of empagliflozin (Jardiance) and insulin degludec (Tresiba) for long-term glycemic durability, cardiovascular outcomes, and real-world treatment decisions in type 2 diabetes.
Read clinical reviewA clinical comparison of empagliflozin (Jardiance) and insulin degludec (Tresiba) covering titration protocols, tolerability profiles, cardiovascular outcomes, and when each drug fits your diabetes management plan.
Read clinical reviewA clinical comparison of empagliflozin (Jardiance) and insulin degludec (Tresiba), including what the evidence says when one stops working and how to decide on the next step.
Read clinical reviewA direct clinical comparison of insulin glargine (Lantus) and insulin degludec (Tresiba) in special populations including older adults, people with renal impairment, pregnancy risk groups, and those prone to hypoglycemia. Covers DEVOTE, ORIGIN, and real-world switching data.
Read clinical reviewA clinical comparison of insulin glargine (Lantus) and insulin degludec (Tresiba) drawing on head-to-head trials, real-world registry data, and current ADA/AACE guidelines to help patients and clinicians make informed basal insulin decisions.
Read clinical reviewA clinical comparison of insulin glargine (Lantus) and insulin degludec (Tresiba), covering pharmacokinetics, trial data, switching protocols, and the rationale and risks of using both together.
Read clinical reviewA head-to-head clinical comparison of insulin glargine (Lantus) and insulin degludec (Tresiba) for long-term glycemic durability, hypoglycemia risk, and when switching makes sense. Reviewed by the HealthRX medical team.
Read clinical reviewA head-to-head clinical comparison of insulin glargine (Lantus) vs insulin degludec (Tresiba) covering titration protocols, hypoglycemia rates, glycemic variability, and when to switch, reviewed by the HealthRX medical team.
Read clinical reviewInsulin glargine (Lantus) and insulin degludec (Tresiba) differ in duration, hypoglycemia risk, and dose flexibility. Learn when to switch, how to convert doses, and what the evidence says about outcomes.
Read clinical reviewA direct clinical comparison of metformin and insulin glargine (Lantus) for long-term glycemic durability in type 2 diabetes, covering landmark trials, HbA1c outcomes, safety, and when switching is appropriate.
Read clinical reviewA head-to-head look at metformin versus insulin glargine (Lantus) across clinical trials and real-world data, covering HbA1c reduction, weight, hypoglycemia risk, cardiovascular outcomes, and when clinicians switch between them.
Read clinical reviewA detailed clinical comparison of metformin and Lantus (insulin glargine) across special populations including elderly patients, CKD, pregnancy, obesity, and type 2 diabetes with cardiovascular disease.
Read clinical reviewA clinical breakdown of metformin vs insulin glargine (Lantus): when to combine them, why the combination works, and the real risks patients and clinicians must weigh.
Read clinical reviewA clinical comparison of metformin and insulin glargine (Lantus) covering titration speed, tolerability, glycemic outcomes, and when to switch or combine both agents.
Read clinical reviewA clinical guide comparing metformin and insulin glargine (Lantus) for type 2 diabetes management, including what steps to take when either drug stops working.
Read clinical reviewA clinical comparison of metformin and insulin degludec (Tresiba) for long-term blood sugar control, covering durability of HbA1c reduction, cardiovascular safety, hypoglycemia risk, and when clinicians switch patients between the two.
Read clinical reviewA clinician-reviewed comparison of metformin and Tresiba (insulin degludec) drawing on UKPDS 34, DEVOTE, and real-world registry data, covering glycemic control, hypoglycemia risk, weight, cardiovascular outcomes, and when switching is appropriate.
Read clinical reviewA clinical comparison of metformin and Tresiba (insulin degludec) across special populations including elderly patients, CKD, pregnancy, and obesity. Evidence-based guidance reviewed by the HealthRX medical team.
Read clinical reviewA physician-reviewed comparison of metformin and insulin degludec (Tresiba), covering why combining them makes clinical sense, who qualifies, and what risks to monitor.
Read clinical reviewA detailed clinical comparison of metformin and insulin degludec (Tresiba) covering titration protocols, tolerability, hypoglycemia risk, and when to switch or combine, reviewed by the HealthRX medical team.
Read clinical reviewA clinical deep-dive comparing metformin and insulin degludec (Tresiba), with guidance on when to switch, how to combine, and what the evidence says about sequencing these two cornerstone diabetes therapies.
Read clinical review